Results of a phase 2 study showed that treatment with pembrolizumab plus low-dose ipilimumab has a significant antitumor activity and is tolerable in melanoma patients who progress on first-line anti-PD1/PDL1 therapy.
For patients with unresectable or metastatic melanoma, first-line treatment with an anti-PD1 or anti-PDL1 antibody is now standard-of-care. The optimal second-line treatment after progression on the anti-PD1/PDL1 treatment is not known yet. Long-term follow-up data of the KEYNOTE-6 study has shown that for those patients who progressed on the PD1 antibody pembrolizumab and received ipilimumab (3 mg/kg), an anti-CTLA4 antibody, in second line, the long-term response rate was 15% with a median overall survival (OS) of 13.6 months . However, ipilimumab given in a dose of 3 mg/kg comes with high toxicity. Data from both KEYNOTE-029 and Checkmate 511 demonstrated that low-dose ipilimumab (1 mg/kg) in combination with an anti-PD1 antibody shows ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Adjuvant pembrolizumab: durable RFS for stage III melanoma Next Article
Toripalimab plus axitinib effective in metastatic mucosal melanoma »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.